CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02893917
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:56.859308+00:00
Published At: 2025-03-30T00:00:00+00:00
Record Updated At: 2026-04-13
Results Posted At: 2025-03-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation", "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation", "Metastatic Prostate Carcinoma", "Prostate Adenocarcinoma With Neuroendocrine Differentiation", "Stage IV Prostate Adenocarcinoma AJCC v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-13"
protocolSection.identificationModule.nctId: "NCT02893917"
protocolSection.identificationModule.officialTitle: "A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-03-30"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.